Introduction to a review series on von Willebrand factor, factor VIII, and factor IX
Edited and introduced by Associate Editor Thomas Ortel, this review series features 3 reviews of von Willebrand factor, factor VIII, and factor IX. These 3
Edited and introduced by Associate Editor Thomas Ortel, this review series features 3 reviews of von Willebrand factor, factor VIII, and factor IX. These 3
Susan Wojcicki, the late CEO of YouTube, had a message for the world just weeks before she passed away in August: “Lung cancer among people…
The AACR and JCA are proud to offer this 13th AACR-JCA Joint Conference which brings together outstanding researchers from the U.S., Japan, and around the…
For starters, it does not mean you have cancer—or that you’re destined to develop it.
During the IWWM-12, the Lymphoma Hub was pleased to speak to Jorge Castillo, Dana-Farber Cancer Institute, Boston, US. We asked, What were the latest updates…
Review key moments from our annual Fall Summit, including session slides, takeaway points, and discussion questions from oncology experts.
Illumination of the inherent heterogeneity within HER2-positive breast cancers through the delineation of distinct molecular subtypes lays the groundwork for developing more personalized treatment strategies…
Abstract. Antibody–drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than…
The combination of sorafenib tosylate, valproic acid, and sildenafil demonstrated activity in a phase 2 trial of patients with high-grade glioma.
Recent research in classifying subtypes of small cell lung cancer is bringing renewed hope for treatment advances. To learn more, we spoke with Carl Gay,…
Press release to promote updated ASTRO clinical guideline for radiation therapy to treat patients with locally advanced rectal cancer